Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial
Authors
Keywords
-
Journal
Clinical Kidney Journal
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2020-10-24
DOI
10.1093/ckj/sfaa225
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
- (2020) Vlado Perkovic et al. DIABETES CARE
- Type 2 diabetes mellitus management in patients with chronic kidney disease: an update
- (2020) Zoi Kleinaki et al. Hormones-International Journal of Endocrinology and Metabolism
- Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
- (2019) Darren K. McGuire et al. CIRCULATION
- SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
- (2019) Pantelis Sarafidis et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later
- (2019) Darren K. McGuire et al. DIABETES OBESITY & METABOLISM
- Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials
- (2019) Carmine Zoccali et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency
- (2019) Andrew S. Levey et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Pharmacologic Glycemic Management of Type 2 Diabetes in Adults
- (2018) Lorraine Lipscombe et al. Canadian Journal of Diabetes
- Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
- (2018) Julio Rosenstock et al. Cardiovascular Diabetology
- Effects of Diabetes Medications Targeting the Incretin System on the Kidney
- (2018) Richard J. MacIsaac et al. Clinical Journal of the American Society of Nephrology
- The State of US Health, 1990-2016
- (2018) et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Change in Proteinuria or Albuminuria as a Surrogate for Cardiovascular and Other Major Clinical Outcomes: A Systematic Review and Meta-analysis
- (2018) Tyrone G. Harrison et al. CANADIAN JOURNAL OF CARDIOLOGY
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
- (2018) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
- (2018) Sandeep R. Das et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Chronic kidney disease, health-related quality of life and their associated economic burden among a nationally representative sample of community dwelling adults in England
- (2018) Nga T. Q. Nguyen et al. PLoS One
- Diabetes with early kidney involvement may shorten life expectancy by 16 years
- (2017) Chi Pang Wen et al. KIDNEY INTERNATIONAL
- Clinicopathological features of diabetic and nondiabetic renal diseases in type 2 diabetic patients with nephrotic-range proteinuria
- (2017) Yu Ho Lee et al. MEDICINE
- Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS
- (2016) Jan H. Cornel et al. DIABETES CARE
- Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
- (2016) Ofri Mosenzon et al. DIABETES CARE
- The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes
- (2016) David Cherney et al. DIABETOLOGIA
- Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014
- (2016) Maryam Afkarian et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
- (2016) Vlado Perkovic et al. KIDNEY INTERNATIONAL
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis
- (2016) Gemma Currie et al. BMC Nephrology
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
- (2014) Benjamin M. Scirica et al. CIRCULATION
- Safety of medical therapy in patients with chronic kidney disease and end-stage renal disease
- (2014) Matthew R. Weir et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen
- (2014) Keizo Kanasaki et al. DIABETES
- Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy
- (2014) Yuliya Sharkovska et al. JOURNAL OF HYPERTENSION
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Age, Renal Dysfunction, Cardiovascular Disease, and Antihyperglycemic Treatment in Type 2 Diabetes Mellitus: Findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study
- (2013) Anna Solini et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Chronic kidney disease: global dimension and perspectives
- (2013) Vivekanand Jha et al. LANCET
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
- (2012) Larry K. Golightly et al. CLINICAL PHARMACOKINETICS
- Nephrotic Syndrome in Diabetic Kidney Disease: An Evaluation and Update of the Definition
- (2009) Nicholas Stoycheff et al. AMERICAN JOURNAL OF KIDNEY DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More